

AP
8/25/15



SEC

15027392

SSION

OMB APPROVAL	
OMB Number:	3235-0123
Expires:	March 31, 2016
Estimated average burden	
hours per response.....	12.00

**ANNUAL AUDITED REPORT
FORM X-17A-5
PART III**

SEC FILE NUMBER
8- 18082



FACING PAGE

**Information Required of Brokers and Dealers Pursuant to Section 17 of the
Securities Exchange Act of 1934 and Rule 17a-5 Thereunder**

REPORT FOR THE PERIOD BEGINNING 07/01/14 AND ENDING 06/30/15
MM/DD/YY MM/DD/YY

A. REGISTRANT IDENTIFICATION

NAME OF BROKER-DEALER: Invemed Associates LLC

OFFICIAL USE ONLY
FIRM I.D. NO.

ADDRESS OF PRINCIPAL PLACE OF BUSINESS: (Do not use P.O. Box No.)

375 Park Avenue

(No. and Street)

New York

New York

10152

(City)

(State)

(Zip Code)

NAME AND TELEPHONE NUMBER OF PERSON TO CONTACT IN REGARD TO THIS REPORT

John Baran

212-421-2500

(Area Code - Telephone Number)

B. ACCOUNTANT IDENTIFICATION

INDEPENDENT PUBLIC ACCOUNTANT whose opinion is contained in this Report*

McGladrey LLP

(Name - if individual, state last, first, middle name)

1185 Avenue of the Americas

New York

(Address)

(City)

New York SECURITIES AND EXCHANGE COMMISSION <small>(State)</small>	10036-2602 <small>(Zip Code)</small>
RECEIVED	
AUG 24 2015	
REGISTRATIONS BRANCH	
11	

CHECK ONE:

- Certified Public Accountant
- Public Accountant
- Accountant not resident in United States or any of its possessions.

FOR OFFICIAL USE ONLY

--

**Claims for exemption from the requirement that the annual report be covered by the opinion of an independent public accountant must be supported by a statement of facts and circumstances relied on as the basis for the exemption. See Section 240.17a-5(e)(2)*

SEC 1410 (06-02)

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Xg


OATH OR AFFIRMATION

I, John Baran, swear (or affirm) that, to the best of my knowledge and belief the accompanying financial statement and supporting schedules pertaining to the firm of Invemed Associates LLC, as of June 30, 2015, are true and correct. I further swear (or affirm) that neither the company nor any partner, proprietor, principal officer or director has any proprietary interest in any account classified solely as that of a customer, except as follows:



Signature
CFO

Title



Notary Public

BEVERLY ANN LEMMON
Notary Public, State of New York
No. 01LE624447
Qualified in New York County
Commission Expires July 11, 2019

This report ** contains (check all applicable boxes):

- (a) Facing Page.
- (b) Statement of Financial Condition.
- (c) Statement of Income (Loss).
- (d) Statement of Changes in Financial Condition.
- (e) Statement of Changes in Stockholders' Equity or Partners' or Sole Proprietors' Capital.
- (f) Statement of Changes in Liabilities Subordinated to Claims of Creditors.
- (g) Computation of Net Capital.
- (h) Computation for Determination of Reserve Requirements Pursuant to Rule 15c3-3.
- (i) Information Relating to the Possession or Control Requirements Under Rule 15c3-3.
- (j) A Reconciliation, including appropriate explanation of the Computation of Net Capital Under Rule 15c3-1 and the Computation for Determination of the Reserve Requirements Under Exhibit A of Rule 15c3-3.
- (k) A Reconciliation between the audited and unaudited Statements of Financial Condition with respect to methods of consolidation.
- (l) An Oath or Affirmation.
- (m) A copy of the SIPC Supplemental Report.
- (n) A report describing any material inadequacies found to exist or found to have existed since the date of the previous audit.

**For conditions of confidential treatment of certain portions of this filing, see section 240.17a-5(e)(3).

Invemed Associates LLC

Statement of Financial Condition

June 30, 2015

Filed as PUBLIC information pursuant to Rule 17a-5(d) under the Securities Exchange Act of 1934

Contents

Independent Auditor's Report	1
Financial Statements:	
Statement of Financial Condition	2
Notes to Statement of Financial Condition	3-9



Report of Independent Registered Public Accounting Firm

To the Member
Invemed Associates LLC
New York, New York

We have audited the accompanying statement of financial condition of Invemed Associates LLC (the Company) as of June 30, 2015, and the related notes (the financial statement). This financial statement is the responsibility of the Company's management. Our responsibility is to express an opinion on this financial statement based on our audit.

We conducted our audit in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statement is free of material misstatement. Our audit included consideration of internal control over financial reporting as a basis for designing audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control over financial reporting. Accordingly, we express no such opinion. An audit also includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statement, assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audit provides a reasonable basis for our opinion.

In our opinion, the financial statement referred to above presents fairly, in all material respects, the financial position of Invemed Associates LLC as of June 30, 2015, in conformity with accounting principles generally accepted in the United States.

McGladrey LLP

New York, New York
August 21, 2015

Invedmed Associates LLC

**Statement of Financial Condition
June 30, 2015**

ASSETS

Cash	\$	294,264
Due From Broker		11,950,026
Note Receivable		3,000,000
Other Receivables		157,132
Due From Affiliate		1,977,190
Securities Owned, at fair value		20,626,196
Other Investments, at fair value		75,754,574
Property and Equipment, less accumulated depreciation of \$ 2,439,630		31,352
Life Insurance		717,404
Other Assets		<u>9,847</u>
Total assets		<u><u>\$ 114,517,985</u></u>

LIABILITIES AND MEMBER'S EQUITY

Liabilities and Accrued Expenses		<u>442,248</u>
Total liabilities		442,248
Commitments, Contingencies and Guarantees		
Member's Equity		<u>114,075,737</u>
Total liabilities and Member's equity		<u><u>\$ 114,517,985</u></u>

See Notes to Statement of Financial Condition.

Invenmed Associates LLC

Notes of Statement of Financial Condition

Note 1. Description of Organization

Invenmed Associates LLC (the "Company") is a wholly owned subsidiary of Invenmed Securities, Inc. (the "Parent"). The Company is registered under the Securities Exchange Act of 1934 as a broker and dealer in securities, and is a member of the New York Stock Exchange ("NYSE").

The clearing and depository operations for the Company's securities transactions on behalf of its customers and for its own proprietary accounts are provided primarily by one broker pursuant to a clearance agreement. At June 30, 2015, all of the Company's securities owned are security positions with the same clearing broker.

The Company operates under the provisions of Paragraph (k)(2)(ii) of Rule 15c3-3 of the Securities Exchange Act of 1934 and, accordingly, is exempt from the remaining provisions of that rule. Essentially, the requirements of Paragraph (k)(2)(ii) provide that the Company clear all transactions on behalf of customers on a fully disclosed basis with a clearing broker-dealer and promptly transmit all customer funds and securities to the clearing broker-dealer. The clearing broker-dealer carries all the accounts of the customers and maintains and preserves all related books and records as are customarily kept by a clearing broker-dealer.

The Company earns commissions as an introducing broker for the transactions of its customers. The clearing and depository operations for the Company's customer accounts and proprietary transactions are performed by its clearing broker. In connection therewith, the Company indemnifies its clearing broker for losses that it may sustain from the customer accounts introduced by the Company.

All the securities owned reflected in the statement of financial condition are positions with this clearing broker. The securities owned are subject to margin requirements.

Note 2. Significant Accounting Policies

Basis of Presentation: The Company follows accounting principles generally accepted in the United States of America ("GAAP"), as established by the Financial Accounting Standards Board (the "FASB"), to ensure consistent reporting of financial condition, results of operations, and cash flows.

Use of Estimates: The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingencies in the financial statements and accompanying notes, as well as the reported amount of revenue and expenses. Actual results could differ from those estimates.

Due From Broker: The clearing and depository operations represent cash of \$11,779,428 maintained at the clearing broker and a receivable of \$170,598 for commissions earned. The Agreement for Securities Clearance Services requires a minimum equity balance of \$300,000, which is included in the aforementioned cash amount.

Note Receivable: The note receivable is deemed to be recorded at fair value as the applicable interest rates reflect current market conditions.

Property and Equipment: Property and equipment are recorded at cost and are depreciated on a straight-line basis over the estimated useful lives of the assets.

Invenmed Associates LLC

Notes of Statement of Financial Condition

Note 2. Significant Accounting Policies (Continued)

Income Taxes: FASB Accounting Standards Codification ("ASC") 740, *Income Taxes*, provided guidance for how uncertain tax positions should be recognized, measured, disclosed and presented in the financial statements. This requires the evaluation of tax positions taken or expected to be taken in the course of preparing the Company's tax returns to determine whether the tax positions are "more likely than not" of being sustained "when challenged" or "when examined" by the applicable tax authority. Tax positions deemed not to meet the more-likely-than-not threshold would be recorded as a tax expense and liability in the current year. For the year ended June 30, 2014, management has determined that there are no uncertain tax positions.

As a single-member limited liability company, the Company is not subject to federal, state or local income taxes. The Company's income or loss is reportable by its Member (Parent) on its corporate income tax return.

The Company is generally not subject to examination by U.S. federal taxing authorities for tax years before 2012 and the state taxing authorities for tax years before 2014.

Recent Accounting Pronouncements: In May 2015, the FASB issued Accounting Standard Update 2015-07 ("ASU 2015-07"), Disclosures for Investments in Certain Entities That Calculate Net Asset Value per Share (or Its Equivalent). ASU 2015-07 removes the requirement to categorize within the fair value hierarchy all investments for which fair value is measured using the net asset value per share practical expedient. ASU 2015-07 will be effective for the Company beginning in the first quarter of calendar year 2016, with early adoption permitted, and will be applied retrospectively. The Company is currently evaluating the impact of ASU 2015-07 on the Company's financial statements.

Note 3. Note Receivable

The Company purchased on January 7, 2015 a 6.5% subordinated convertible note due 2021 in the amount of \$3,000,000. The principle note may be converted for 66.66 shares of common stock for each \$1,000 principal amount of notes or \$15.00 per share.

Note 4. Property and Equipment

Equipment, furniture, fixtures and leasehold improvements, at cost, consists of the following:

Leasehold improvements	\$ 1,109,031
Computer equipment and software	919,300
Furniture and fixtures	<u>442,651</u>
	2,470,982
Less accumulated depreciation	<u>(2,439,630)</u>
	<u>\$ 31,352</u>

Invemed Associates LLC

Notes of Statement of Financial Condition

Note 5. Investments at Fair Value

FASB ASC 820, *Fair Value Measurements and Disclosures*, defines fair value, establishes a fair value hierarchy based on the quality of inputs used to measure fair value, and provides for disclosure requirements for fair value measurements. Fair value is the price that would be received to sell an asset and paid to transfer a liability in an orderly transaction between market participants at the measurement date. The Company utilizes valuation techniques to maximize the use of observable inputs and minimize the use of unobservable inputs. Assets and liabilities recorded at fair value are categorized based upon the level of judgment associated with the inputs used to measure their value. The fair value hierarchy gives the highest priority to quoted prices in active markets for identical assets or liabilities (Level 1) and lowest priority to unobservable inputs (Level 3). Inputs are broadly defined as assumptions market participants would use in pricing an asset or liability. The three levels of the fair value hierarchy are described below:

- Level 1: Quoted prices for identical assets and liabilities traded in active exchange markets, such as the New York Stock Exchange.
- Level 2: Quoted prices which are not active, or inputs that are observable (either directly or indirectly) for substantially the full term of the asset or liability;
- Level 3: Prices, inputs or exotic modeling techniques which are both significant to the fair value measurement and unobservable (supported by little or no market activity).

As required by ASC 820, investments are classified within the level of the lowest significant input considered in determining fair value. Investments classified within Level 3 are those whose fair value measurement consider several inputs and may include Level 1 or Level 2 inputs as components of the overall fair value measurement. The table that follows sets forth information about the level within the fair value hierarchy at which the Company's investments are measured at June 30, 2015.

Marketable Securities consist of equity securities and are stated at quoted fair value. Investments in marketable securities traded on a national securities exchange are stated at the last sale price on the day of valuation.

The carrying amount of money market funds and certificate of deposit assessment rate ("CDAR") approximate fair value because the investments are liquid in nature and have short-term maturities.

Depending on the redemption options available, as a practical expedient it may be possible that for investments in other investment partnerships, the reported net asset value ("NAV") represents fair value based on observable data such as ongoing redemption and/or subscription activity. In certain cases, the NAV is considered as a Level 2 input. However, certain funds may provide the manager with the ability to suspend or postpone redemptions (a "gate"), or to create "side-pockets" that cannot be redeemed. In the case of the imposition of a gate, or if the Company may not redeem its holdings in the fund within 90 days or less, the investment is generally classified as Level 3.

Investments in other investment entities are valued at fair value based on the applicable percentage ownership of the underlying partnerships' net assets as of the measurement date, as determined by management. These investments have no readily determinable fair value and follow industry practice consistent with the measurement principles in the Financial Services – Investments Companies Topic of the FASB ASC. In determining fair value, management utilizes valuations provided by the underlying investment partnerships. The underlying investment partnerships value securities and other financial instruments on a fair value basis of accounting. The estimated fair values of certain investments of the underlying investment partnerships, which may include private placements and other securities for which prices are not readily available, are determined by the management or sponsor of the respective other investment partnership and may not reflect amounts that could be realized upon immediate sale, or amounts that ultimately may be realized. Accordingly, the estimated fair values may differ significantly from the values that would have been used had a ready market existed for these investments. The fair value of the Company's investments in other investment partnerships generally represents the amount the Company would expect to receive if it were to

Invenmed Associates LLC

Notes of Statement of Financial Condition

Note 5. Investments at Fair Value (Continued)

liquidate its investment in the other investment partnerships excluding any redemption charges that may apply.

A description of the valuation techniques applied to the Company's major categories of assets and liabilities measured at fair value on a recurring basis follows.

	<u>Level 1</u>	<u>Level 2</u>	<u>Level 3</u>	<u>Total</u>
Securities Owned:				
Equities	\$ 5,626,196	\$ -	\$ -	\$ 5,626,196
Money Market and Certificate of Deposit Assessment Rate ("CDAR")	<u>15,000,000</u>	<u>-</u>	<u>-</u>	<u>15,000,000</u>
Total securities owned	<u>\$ 20,626,196</u>	<u>\$ -</u>	<u>\$ -</u>	<u>\$ 20,626,196</u>
Other Investments:				
Investments in investment entities	<u>\$ -</u>	<u>\$ -</u>	<u>\$ 75,754,574</u>	<u>\$ 75,754,574</u>

The Company assesses the levels of investments at each measurement date, and transfers between levels are recognized on the actual date of the event that caused the transfers in accordance with the Company's accounting policy regarding the recognition of transfers between levels of the fair value hierarchy. For the year ended June 30, 2015, there were no transfers.

The following is a reconciliation of the beginning and ending balances for assets and liabilities measured at fair value on a recurring basis using significant unobservable inputs (Level 3) during the year ended June 30, 2015:

	<u>Beginning Balance</u>	<u>Realized Gains</u>	<u>Unrealized Gains</u>	<u>Net Contributions</u>	<u>Distributions</u>	<u>Ending Balance</u>
Other investments	<u>\$ 86,151,312</u>	<u>17,062,973</u>	<u>(12,076,062)</u>	<u>2,892,292</u>	<u>(18,275,941)</u>	<u>\$ 75,754,574</u>

There were no transfers between Level 1, Level 2 and Level 3 during the year.

Other investments, which have been valued at an estimated fair value as determined by management in the absence of readily ascertainable market values, consist of investments in limited partnerships and restricted common and preferred stocks.

Because of the inherent uncertainty of valuation, those estimated values may differ significantly from the values that would have been used had a ready market for the investments existed, and the differences could be material.

The following table sets forth additional disclosures of the Company's investments whose fair value is estimated using net asset value per share (or its equivalent) as of June 30, 2015:

Invenmed Associates LLC

Notes of Statement of Financial Condition

Note 5. Investments at Fair Value (Continued)

Investment	Strategy	% of Member's Equity	Fair Value	Redemption Frequency	Redemption Notice Period	Remaining Lock-Up Period
Lone Cascade LP	Long Only Global Equities	8.60%	\$ 9,811,528	Quarterly	30 days	None
Swiftcurrent Partners, LP	U.S. Equity Long/Short	5.20%	5,927,858	Annually	60 days	None
Marlin Sams Fund LP	Value Oriented	8.45%	9,641,230	Annually	45 days	None
Pointstate Fund LP	Macro and Long/Short Equity	24.71%	28,189,068	Quarterly	90 days	None
Other Investment entities (*)	Long/Short	18.50%	21,106,466	None to Annually	None to 95 days	None
Total investment in investment entities		<u>65.46%</u>	<u>\$ 74,676,150</u>			

(*) Based on the available information, no underlying investment of the other investment entities represents greater than 5% of Member's equity.

The investments in investment entities includes investments in hedge funds whose objective is to seek above-average rates of return and long-term capital growth. In addition, certain hedge funds own marketable securities to provide liquidity when needed. Additionally, other investments include \$1,078,424 of restricted securities which are not estimated using net asset value.

Note 6. Net Capital Requirement

The Company is subject to the Securities and Exchange Commission Uniform Net Capital Rule ("SEC Rule 15c3-1" or the "Rule"), which requires the maintenance of minimum net capital. The Company has elected to use the alternative method permitted by the Rule, which requires that the Company maintain minimum net capital equal to the greater of \$250,000 or 2% of the aggregate debit balances arising from customer transactions, as defined. At June 30, 2015, the Company had net capital of \$28,872,646, which exceeded its requirement of \$250,000 by \$28,572,646.

Note 7. Guarantees and Indemnifications

The Company is required to disclose information about its obligations under certain guarantee arrangements. Guarantees are defined as contracts and indemnification agreements that contingently require a guarantor to make payments to the guaranteed party based on changes in an underlying interest or foreign exchange rate, security or commodity price, an index or the occurrence or nonoccurrence of a specified event related to an asset, liability or equity security of a guaranteed party. The Company may obtain short-term financing from the clearing brokers from whom it can borrow against its proprietary inventory, subject to collateral maintenance requirements.

In the normal course of business, the Company enters into contracts that contain a variety of representations and warranties that provide indemnifications under certain circumstances. The Company's maximum exposure under these arrangements is unknown, as this would involve future claims that may be made against the Company that have not yet occurred. The Company expects the risk of future obligation under these indemnifications to be remote.

The Company maintains cash in bank deposit accounts which, at times, may exceed federally insured limits. The Company has not experienced any losses to date.

Invemed Associates LLC

Notes of Statement of Financial Condition

Note 7. Guarantees and Indemnifications (Continued)

In the normal course of business, customers may sell securities short. Subsequent market fluctuations may require the clearing broker to obtain additional collateral from the Company's customers. It is the policy of the clearing broker to value the short positions weekly and to obtain additional deposits where it is deemed appropriate.

Note 8. Off-Balance-Sheet Risk and Concentration of Credit Risk

The Company conducts business with several broker-dealers and organizations for its trading activities. The clearing and depository operations of the Company's trading activities are performed by these brokers pursuant to agreements. The Company monitors the credit standing of these brokers on an ongoing basis. In the event a broker is unable to fulfill its obligations, the Company would be subject to credit risk.

The Company's financial instruments that are exposed to concentrations of credit risk consist primarily of cash. The Company maintains its cash accounts at financial institutions located in the United States. At times, the Company may have cash that exceeds the balance insured by the Federal Deposit Insurance Corporation. The Company monitors such credit risks and has not experienced any losses related to such risks.

Note 9. Commitments

The Company's office facilities are leased under a noncancelable operating lease expiring December 2022. The lease contains provisions for rent escalations based on certain costs incurred by the lessor. The aggregate future minimum annual rental commitments are as follows:

Year ending June 30,

2016	\$	1,161,800
2017		1,179,500
2018		1,179,500
2019		1,179,500
2020		1,197,000
Thereafter		<u>1,922,958</u>
	\$	<u>7,820,258</u>

Included in other investments are unfunded commitments of \$4,382,487 as of June 30, 2015.

<u>Investment</u>	<u>Fair Value</u>	<u>Unfunded Commitment</u>
Centerview Capital LP	\$ 1,338,322	\$ 478,704
Tullis Growth Fund	688,949	750,000
Amberbrook III LLC	277,406	153,783
Columbus Hill Opportunities Fund, L.P.	-	<u>3,000,000</u>
	\$ 2,304,677	\$ 4,382,487

Invenmed Associates LLC

Notes of Statement of Financial Condition

Note 10. Related Party Transactions

The Company entered into a Transportation Services agreement with the Parent on July 1, 2007. Under this agreement, the Company utilizes the airplane on an as-needed basis for flights. In consideration of this agreement, the Company pays the Parent \$8,000 per flight hour plus actual flight charges as billed by the airplane's management company.

During fiscal 2015 the Company made advances to its parent totaling \$ 1,911,190 with no specified repayment terms.

The Company has an investment with an investment partnership, the Marlin Sams Fund LP, for \$9,641,230. The Marlin Sams Fund LP has an investment in an affiliate of the Company for \$6,267,973 and an unfunded commitment of \$3,844,110.

Note 11. Profit-Sharing Plan

The Company has a profit-sharing plan covering all employees. The plan provides for the Company to contribute up to 15% of employees' fiscal year-end compensation, subject to certain limitations as defined in the plan agreement.

All participants' account balances are fully vested at all times.

Note 12. Subsequent Events

The Company has evaluated subsequent events for potential recognition and/or disclosure through August 21, 2015, the date the financial statements were available to be issued, noting none.